What is Lifesci Capital’s Forecast for TCRX FY2024 Earnings?

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Analysts at Lifesci Capital lowered their FY2024 earnings estimates for TScan Therapeutics in a note issued to investors on Tuesday, November 12th. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($1.08) per share for the year, down from their prior forecast of ($1.07). The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share. Lifesci Capital also issued estimates for TScan Therapeutics’ FY2025 earnings at ($1.08) EPS.

A number of other equities research analysts also recently weighed in on TCRX. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, November 12th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Friday. Finally, Wedbush reiterated an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Stock Down 8.5 %

Shares of NASDAQ TCRX opened at $4.41 on Friday. TScan Therapeutics has a 12-month low of $3.73 and a 12-month high of $9.69. The stock’s fifty day simple moving average is $5.31 and its two-hundred day simple moving average is $6.48. The stock has a market capitalization of $233.62 million, a PE ratio of -4.16 and a beta of 0.79. The company has a current ratio of 9.56, a quick ratio of 7.77 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.03. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.

Institutional Trading of TScan Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in shares of TScan Therapeutics in the second quarter worth about $70,000. SG Americas Securities LLC purchased a new position in TScan Therapeutics during the 3rd quarter worth approximately $78,000. The Manufacturers Life Insurance Company acquired a new stake in TScan Therapeutics during the 2nd quarter valued at approximately $90,000. XTX Topco Ltd purchased a new stake in shares of TScan Therapeutics in the 3rd quarter valued at $112,000. Finally, MetLife Investment Management LLC increased its stake in shares of TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after acquiring an additional 13,164 shares during the period. Hedge funds and other institutional investors own 82.83% of the company’s stock.

Insiders Place Their Bets

In other news, insider Zoran Zdraveski sold 164,686 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the sale, the insider now directly owns 4,716 shares of the company’s stock, valued at $27,258.48. The trade was a 97.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Barbara Klencke bought 5,000 shares of TScan Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was purchased at an average price of $5.53 per share, with a total value of $27,650.00. Following the purchase, the director now directly owns 40,000 shares in the company, valued at $221,200. The trade was a 14.29 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 15,000 shares of company stock valued at $82,550. 2.76% of the stock is currently owned by corporate insiders.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.